← ANALYST RATINGS · TIPRANKS
Pacira Pharmaceuticals (PCRX): analyst forecast and price target
Analyst consensus
Hold0 Buy9 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $34.79, the highest $36.50, the lowest $25.00. The average is −4.3% from the last price of $36.34.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Hardik Parikh★★★★★★★★★★#11483 · hits 28% · avg −12.1% | J.P. Morgan | $23.00 → $36.50+58.7% | Hold | +0.4% | Upgrade | 12.10.26on TipRanks Oct 13 08:14 | +0.2%next day −0.1% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $28.00 → $36.50+30.4% | Hold | +0.4% | Reiterated | 09.10.26on TipRanks 08:50 | −0.8%next day +0.2% · 5 days +2.1% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $38.00 → $36.50−3.9% | Hold | +0.4% | Downgrade | 09.10.26on TipRanks 06:15 | −0.8%next day +0.2% · 5 days +2.1% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $30.00 → $27.00−10.0% | Hold | −25.7% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $30.00 → $27.00−10.0% | Hold | −25.7% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $31.00 → $27.00−12.9% | Hold | −25.7% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $28.00 → $26.00−7.1% | Hold | −28.5% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $31.00 → $29.00−6.5% | Buy | −20.2% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $28.00 → $27.00−3.6% | Hold | −25.7% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| Douglas Miehm★★★★★★★★★★#2559 · hits 51% · avg +5.3% | RBC Capital | $25.00 → $36.50+46.0% | Hold | +0.4% | Assigned | 08.10.26on TipRanks Oct 9 08:35 | +44.8%next day −0.8% · 5 days +0.1% | ↗ |
| Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% | Truist Financial | — | Hold | — | Downgrade | 08.10.26on TipRanks 13:30 | +44.8%next day −0.8% · 5 days +0.1% | ↗ |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $36.00 | Hold | −0.9% | Downgrade | 08.10.26on TipRanks 12:45 | +44.8%next day −0.8% · 5 days +0.1% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | — | Hold | — | Downgrade | 08.10.26on TipRanks 11:45 | +44.8%next day −0.8% · 5 days +0.1% | ↗ |
| Name not given | — | $31.00 → $36.50+17.7% | Hold | +0.4% | Downgrade | 07.10.26on TipRanks 09:10 | +2.0%next day +44.8% · 5 days +45.4% | ↗ |
| Jenna Davidner★★★★★★★★★★#10265 · hits 25% · avg −5.3% | Barclays | $25.00 | Hold | −31.2% | Reiterated | 17.08.26on TipRanks 04:55 | +1.5%next day +3.9% · 5 days +8.2% | ↗ |
| Unknown Analyst | Jefferies | $36.00 | Buy | −0.9% | Reiterated | 09.01.26on TipRanks 09:15 | −10.2%next day −2.7% · 5 days −18.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Pacira Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $29.14 at a price of $25.05 (+16.3%); now: $34.79 at $36.34 (−4.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 1 |
| Buy | 3 | 4 | 4 | 5 | 6 | 6 |
| Hold | 3 | 2 | 1 | 2 | 3 | 11 |
| Sell | 1 | 0 | 0 | 1 | 1 | 1 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.73 (from $0.52 to $0.82). Last quarter: $0.73.
Sales
Next quarter’s sales estimate — $183M (from $177M to $187M). Last quarter: $192M.
Best top-analyst consensus in the sector · Healthcare
About Pacira Pharmaceuticals
- CEO: Frank D. Lee
- Employees: 827
- 2000 Sierra Point Parkway, Brisbane, CA, 94005, US
- www.pacira.com
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Data from the stock’s TipRanks forecast page, read 8 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗